Shedding that begins during semaglutide or tirzepatide use is usually telogen effluvium. The published literature attributes it primarily to rapid weight loss and the micronutrient shortfall that travels with it, rather than to the drug acting on the follicle directly. It characteristically appears two to three months after the shock that caused it, and it is usually temporary.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference on a side effect, not advice about what to do for it. It sets out what the published studies actually report, why the shedding tends to arrive months rather than days into a course, and what a record worth keeping holds. It names no remedy and recommends no supplement, and the section further down explains why that is deliberate rather than an omission.
| Property | Value |
|---|---|
| What it is called | Telogen effluvium — diffuse shedding across the scalp rather than patches or a receding line |
| Typical delay | Two to three months between the trigger and the visible shedding |
| What pooled data show | Higher risk than placebo across interventional trials — risk ratio 3.252, and a single-arm event rate of 3.9 percent (Cheng & Chang, 2026) |
| Reported most with | Semaglutide and tirzepatide carry the highest reporting signals in the class (Viquez Burboa et al., 2026) |
| Scarring or non-scarring | Non-scarring — the follicle is not destroyed as it is in a scarring alopecia |
Pooling only interventional trials, Cheng & Chang, Diabetes Research and Clinical Practice 2026 report a risk ratio of 3.252 for hair loss against placebo across nine studies and 4,114 users, and an event rate of 3.9 percent in the single-arm analysis. A raised relative risk against a small underlying rate is the honest way to read that: more common than on placebo, still uncommon in absolute terms.
The largest record-based study to date, Tang et al., BMJ 2026, emulated a trial on Penn Medicine electronic health records and found a hazard ratio of 1.37 against SGLT-2 inhibitors and 1.68 against DPP-4 inhibitors for incident alopecia. Those authors note explicitly that the absolute risk is low, and that qualification belongs with the figure wherever it is quoted.
Viquez Burboa et al., Skin Appendage Disorders 2026 pooled 17 studies and 1,091,743 patient-exposures, and separated the subtypes. Telogen effluvium came out at an adjusted odds ratio of 1.76 at 12 months, and the authors attribute the effect primarily to weight-loss-induced micronutrient deficiency rather than to any direct action on the follicle. Kang et al., Annals of Dermatology 2024 supply the control case for that reading: 140 patients with the same shedding, triggered by rapid weight loss, with no GLP-1 anywhere in the picture.
This literature is young, and it is worth saying so plainly. The largest and best-designed studies all arrived in 2026, a systematic review published in 2025 reported conflicting findings across the handful of studies available to it, and several of the most widely quoted early reports are brief research letters. What follows describes what is currently published, not a settled account.
Hair follicles cycle between a growing phase and a resting phase, and at any moment a healthy scalp has a small minority sitting in the resting one. A physiological shock pushes far more of them into that resting phase at the same time. Nothing visible happens at the point of the shock, because a resting hair stays in place until the follicle restarts and pushes it out.
That release comes two to three months later, and it comes as a group, which is why it reads as sudden. The shedding people notice in the shower or on the pillow in month three is the delayed echo of something that happened in month one. It is also why the timing misleads: by the time hair is coming out, the early weeks feel like ancient history and the connection is easy to miss. A dated record closes that gap, because the trigger and the shedding sit on the same timeline instead of in memory.
The most useful finding in this literature comes from a study with no GLP-1 in it. Kang et al. examined 140 people with weight-loss-induced telogen effluvium and found it clustering at a mean loss of 15.21 percent of body weight, arriving at a mean rate of 3.54 kg per month. The same shedding, on the same delay, from rapid loss alone.
That is what makes the Viquez Burboa reading persuasive: pooling more than a million patient-exposures, they land on weight-loss-induced micronutrient shortfall as the primary mechanism rather than an effect on the follicle. The drug is upstream of the shedding, not adjacent to it.
There is a second-order effect worth naming. Appetite suppression works, and the intake drop that follows can be considerably larger than intended, because the usual signal that you have eaten too little is the thing the drug is quietening. Someone eating a third of what they used to may not feel they are undereating at all. That is a question for whoever directs your use, and it is a question a record answers far better than a recollection does.
One more note on the Kang finding, because it cuts against intuition: women in that study developed shedding at less severe degrees of weight loss than men, as did older adults. A rate of loss that one person tolerates is not a rate that generalises.
Shedding has several possible drivers and they overlap, which is why sorting them out is an examination and usually a blood test rather than a guess. The list below is a description of the ground a clinician typically covers, offered so you can walk into the appointment knowing what is likely to come up. It is not a checklist to action yourself, and none of these are things to go and address on your own reading of a web page.
Which of the causes above applies in your case is not something a web page can determine, and the answer changes what should happen next. A supplement chosen from a symptom rather than from a result is a guess, and it can be the wrong guess in both directions: correcting nothing, or loading something that was never short to begin with. Several of the micronutrients named above are ones where more is not better.
There is also a timing problem specific to this condition. Because telogen effluvium runs on a two-to-three month delay, anything started today sits in the same window as the shedding settling on its own, and the two are indistinguishable from the inside. That makes self-directed intervention unusually hard to read, and unusually easy to credit wrongly. What Pepti contributes is the dated record that makes the timeline legible to someone qualified to interpret it.
Shedding is a timing question before it is anything else, and timing is exactly what memory handles worst. A record worth keeping holds the following.
The evidence references for semaglutide and tirzepatide cover what the trials report for each compound and what a clean record holds, and how to track peptide cycles sets out the record-keeping method in full.
The published work points primarily at the weight loss rather than at a direct action on the follicle. Viquez Burboa et al., Skin Appendage Disorders 2026 attribute the effect mainly to weight-loss-induced micronutrient deficiency, and Kang et al., Annals of Dermatology 2024 describe the same pattern of shedding in people losing weight rapidly with no GLP-1 involved at all. The distinction matters for what you record, because it points at the rate of loss and at what is actually being eaten rather than at the injection.
Typically two to three months after the trigger rather than at the time of it. Telogen effluvium runs on a delay: a physiological shock moves an unusually large share of follicles into their resting phase at once, and those hairs are not released until that phase ends. The lag is why shedding often surprises people who felt fine through the early weeks, and why the start date is worth writing down when it happens.
Telogen effluvium is generally described as self-limiting, with a high rate of remission. That is a description of how the condition usually behaves across populations, not a promise about any particular person, and this page does not make one. What happens in an individual case is a question for a clinician who can see your history and your bloods.
Telogen effluvium is classified as non-scarring, which means it does not destroy the follicle the way a scarring alopecia does. Not every kind of shedding is telogen effluvium, though, and only a clinician examining you can say which one is in front of them. That is precisely why this page describes what a work-up usually covers instead of telling you what your outcome will be.
Kang et al., Annals of Dermatology 2024 found that women developed weight-loss-related telogen effluvium at less severe degrees of loss than men did, and that the same held for older adults. In that study the men who developed it had generally been losing weight faster. Reporting in the wider literature also skews female, which may reflect both that difference in threshold and a difference in how readily shedding gets noticed and raised.
Shedding that keeps worsening, shedding that has run for many months, patchy loss rather than diffuse thinning, or any visible change to the scalp itself are all reasons to have it looked at rather than waited out. Pepti assesses none of that. What it can do is hand you a dated record of when the shedding started set against your rate of loss, which is worth more in the room than a recollection.
This page is a reference on published evidence and record-keeping. It describes a reported side effect; it does not diagnose one, and it recommends no supplement, no remedy and no course of action for it. It provides no dose figure, no titration amount, and no schedule. Hair shedding that concerns you is a matter for a clinician and for whoever directs your use.
Track it all in Pepti — the weekly log, the site sequence, the vial count and the weight trend, kept in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store